Clinical Trial Update: OP-1 Putty for Posterolateral Fusions [NA]

View source ↗

Summary

Clinical trial update indicates that the OP-1 Putty posterolateral fusion study for degenerative lumbar spondylolisthesis has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Degenerative Lumbar Spondylolisthesis

Drugs mentioned

• OP-1 Putty (recombinant human osteogenic protein-1 (OP-1) putty)

Snippet

Sponsor: Olympus Biotech Corporation | Conditions: Degenerative Lumbar Spondylolisthesis | NA | Status: COMPLETED